SPOTLIGHT: Senetek inks new rights pact

Senetek of Napa, California, has signed a new agreement giving Valeant Pharmaceuticals expanded distribution rights for Kinetin and exclusive marketing rights to Zeatin in exchange for $37 million in guaranteed royalties over the next five years. Release

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.